Hengrui Pharmaceutical (01276): SHR-4610 injection, SHR-1826 for injection, SHRA2009 for injection, Ruikang trastuzumab for injection, and SHR-8068 injection approved for clinical trials

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, the company's subsidiaries, Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-4610 injections, SHR-1826 for injection, Recon trastuzumab for injections, and SHR-8068 injections, which will conduct clinical trials in the near future. SHRA2009